Adaptive Biotechnologies Corp vs CSX Corporation — how do they compare? Adaptive Biotechnologies Corp trades at $25.5 (market cap $4.04B), while CSX Corporation trades at $50.03 (market cap $92.55B). The key difference: CSX Corporation is far larger — about 22.9× Adaptive Biotechnologies Corp's market cap, and CSX Corporation pays a 1.12% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | CSX | |
|---|---|---|
Market Cap | $4.04B | $92.55B |
Sector | Health | Industrials |
52-Week High | $25.45 | $53.21 |
52-Week Low | $12.30 | $32.05 |
Enterprise Value | $4.10B | $110.52B |
Dividend Yield | — | 1.12% |
Trailing returns across standard periods
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →